

# Smoking Cessation Drugs: World Market Prospects 2012-2022

<https://marketpublishers.com/r/S57F54886E8EN.html>

Date: April 2012

Pages: 116

Price: US\$ 2,633.00 (Single User License)

ID: S57F54886E8EN

## Abstracts

Why the smoking treatment market can grow - discover its potential now

What are the commercial prospects for anti-smoking treatments? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.

Our investigation gives you business research and analysis with sales forecasts. It lets you assess forecasted sales at world market, submarket, product and national level to 2022.

You find analysis of prescription (Rx) and over-the-counter (OTC) therapies for smoking. How will leading products - including Nicorette, Nicotinell and Champix/Chantix - perform from 2012? Our report gives predictions and discussions of sales potential.

Also, you see forecasting of therapeutic categories to 2022, finding potential revenues:

Over-the-counter (OTC) smoking cessation products

Prescription (Rx) drugs

Nicotine replacement therapy (NRT)

Nicotine receptor partial agonists

Antidepressant therapy segment.

Our study lets you assess the anti-smoking R&D pipeline too, seeing trends and opportunity. You find discussions of treatments in development:

Nicotine vaccines

Monoamine oxidase inhibitors

Cannabinoid receptor-1 antagonists

Dopamine D3 antagonists

Opiate antagonists

Other agents for smoking therapy.

What does the future hold? From 2012 to 2022, the pharmaceutical industry will improve treatments for smoking cessation, with our report predicting revenue growth. R&D is promising. New formulations and generics will be important too.

Innovations in drug delivery and rising demand in developing countries will also stimulate the industry and market. The study shows you technological and commercial possibilities.

What about leading companies? Our work discusses Pfizer, GSK, Novartis and other players. You see where companies are heading from 2012.

You can investigate the future of medicine for smoking cessation now, finding revenue potentials and other trends.

Sales forecasts, market shares, developmental trends and discussions

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 34 tables, 29 charts and three research interviews.

Eight ways Smoking Cessation Drugs: World Market Prospects 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

Find potential revenues to 2022 for the world market and submarkets

Discover projected revenue trends of leading products to 2022

See market forecasting to 2022 for the US, Japan, EU5, China and India

Assess leading companies, discovering activities and outlooks

Review R&D, seeing pipeline trends by therapeutic area

Investigate competition and opportunities influencing sales

Find out what will stimulate and restrain the industry and market

View opinion from our survey, seeing interviews with authorities.

There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.

Without our report, you could miss information that your competitors are using.

Gain business research and analysis now for anti-smoking medications

Our study is for everybody needing industry and market analyses for treatments to stop smoking. You find data, trends and answers there. Please order that report now.

## Contents

### **1. EXECUTIVE SUMMARY**

- 1.1 Smoking Cessation Drugs: World Market Overview
- 1.2 Aims and Format of the Report
- 1.3 Research and Analysis Methods
- 1.4 Scope of the Report

### **2. INTRODUCTION TO SMOKING CESSATION**

- 2.1 Tobacco
  - 2.1.1 Types of Tobacco Consumption
  - 2.1.2 Tobacco Smoking is a Major Challenge for Healthcare Worldwide
- 2.2 Smoking-Related Health Disorders
- 2.3 Nicotine Addiction
- 2.4 Smoking Cessation
  - 2.4.1 Why is it Difficult to Stop Smoking?
  - 2.4.2 Methods for Smoking Cessation

### **3. WORLD SMOKING CESSATION DRUGS MARKET TO 2022**

- 3.1 Smoking Cessation Drugs Market by Use
  - 3.1.1 Over-the-Counter (OTC) Smoking Cessation Drugs, 2010
    - 3.1.1.1 OTC Smoking Cessation Drugs: Forecast, 2012-2022
  - 3.1.2 Prescription (Rx) Smoking Cessation Drugs, 2010
    - 3.1.2.1 Prescription Smoking Cessation Drugs: Forecast, 2012-2022
- 3.2 Smoking Cessation Drugs by Mechanism of Action
  - 3.2.1 Nicotine Replacement Therapy
    - 3.2.1.1 Nicotine Replacement Therapy, 2010
    - 3.2.1.2 Nicotine Replacement Therapy Forecast, 2012-2022
  - 3.2.2 Nicotine Receptor Partial Agonist Drugs
    - 3.2.2.1 Nicotine Receptor Partial Agonist Drugs, 2010
    - 3.2.2.2 Nicotine Receptor Partial Agonist Drugs Forecast, 2012-2022
  - 3.2.3 Antidepressants
    - 3.2.3.1 Antidepressants for Smoking Cessation, 2010
    - 3.2.3.2 Antidepressants for Smoking Cessation: Forecast, 2012-2022

### **4. LEADING NATIONAL MARKETS FOR SMOKING CESSATION DRUGS TO 2022**

- 4.1 The Leading Smoking Cessation Markets, 2010
- 4.2 The US Smoking Cessation Market
  - 4.2.1 Smoking Prevalence Declining in US
  - 4.2.2 Availability and Reimbursement of Smoking Cessation Aids in the US
  - 4.2.3 US Smoking Cessation Market Revenue, 2010
  - 4.2.4 US Smoking Cessation Market Forecast, 2012-2022
  - 4.2.5 Scope for US Smoking Cessation Market Expansion
- 4.3 The Japanese Smoking Cessation Market
  - 4.3.1 Japan has a Less Developed Smoking Cessation Market
  - 4.3.2 The Japanese Smoking Cessation Market, 2010
  - 4.3.3 Japanese Smoking Cessation Market Forecast, 2012-2022
- 4.4 The Top 5 EU Smoking Cessation Markets (EU5 Countries)
  - 4.4.1 The UK Smoking Cessation Market
    - 4.4.1.1 Tobacco Use in the UK
    - 4.4.1.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales
  - OTC Retailing of NRT
    - 4.4.1.3 The UK is Europe's Largest Smoking Cessation Market
    - 4.4.1.4 UK Government Anti-Smoking Legislation Lifts Market
    - 4.4.1.5 UK Smoking Cessation Market, 2010
    - 4.4.1.6 UK Smoking Cessation Market Forecast, 2012-2022
  - 4.4.2 The French Smoking Cessation Market
    - 4.4.2.1 French Smoking Prevalence
    - 4.4.2.2 The French Smoking Cessation Market, 2010
    - 4.4.2.3 French Government's Provision of Smoking Cessation Aid Reimbursement
    - 4.4.2.4 French Smoking Cessation Market Forecast, 2012-2022
  - 4.4.3 The Spanish Smoking Cessation Market
    - 4.4.3.1 Smoking Bans in Spain
    - 4.4.3.2 The Spanish Smoking Cessation Market, 2010
    - 4.4.3.3 The Spanish Smoking Cessation Market Forecast, 2012-2022
  - 4.4.4 The Italian Smoking Cessation Market
    - 4.4.4.1 Smoking Bans in Italy
    - 4.4.4.2 The Italian Smoking Cessation Market, 2010
    - 4.4.4.3 The Italian Smoking Cessation Market Forecast, 2012-2022
  - 4.4.5 The German Smoking Cessation Market
    - 4.4.5.1 The German Smoking Cessation Market, 2010
    - 4.4.5.2 Factors Holding Back the German Smoking Cessation Market
    - 4.4.5.3 German Smoking Cessation Market Forecast, 2012-2022
- 4.5 The Chinese Smoking Cessation Market

- 4.5.1 More than 5 Billion Cigarettes are Smoked in China Every Day
- 4.5.2 The Chinese Smoking Cessation Market, 2010
- 4.5.3 The Chinese Smoking Cessation Market is Under Developed
- 4.5.4 Smoking Cessation Market Prospects in China
- 4.5.5 Chinese Smoking Cessation Market Forecast, 2012-2022
- 4.6 The Indian Smoking Cessation Market
  - 4.6.1 Tobacco Use in India
  - 4.6.2 The Indian Smoking Cessation Market, 2010
  - 4.6.3 Indian Smoking Cessation Market Still in its Infancy
  - 4.6.4 Prospects for Growth of the Indian Smoking Cessation Market
  - 4.6.5 Indian Smoking Cessation Market Forecast, 2012-2022

## **5. LEADING SMOKING CESSATION PRODUCTS: OUTLOOK TO 2022**

- 5.1 The Top 5 Brands Claimed Most of the Market in 2010
- 5.2 Nicotine Replacement Therapy
  - 5.2.1 NiQuitin/Nicabate/NicoDerm CQ (GSK)
    - 5.2.1.1 NiQuitin/Nicabate/NicoDerm CQ Sales, 2010
    - 5.2.1.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast, 2012-2022
  - 5.2.2 Nicorette (Johnson & Johnson/Takeda/Perrigo Company)
    - 5.2.2.1 Nicorette Sales, 2010
    - 5.2.2.2 Nicorette Sales Forecast, 2012-2022
  - 5.2.3 Nicotinell (Novartis)
    - 5.2.3.1 Nicotinell Sales, 2010
    - 5.2.3.2 Nicotinell Sales Forecast, 2012-2022
  - 5.2.4 Other NRT Products
- 5.3 Champix/Chantix (Varenicline, Pfizer)
  - 5.3.1 Champix/Chantix Sales, 2010
  - 5.3.2 Champix/Chantix Sales Forecast, 2012-2022
  - 5.3.3 Champix/Chantix May Help in Treating Alcohol Addiction
- 5.4 Zyban (Bupropion, GSK)
  - 5.4.1 Zyban Sales, 2010
  - 5.4.2 Zyban Sales Forecast, 2012-2022
- 5.5 Summary of Leading Smoking Cessation Brands, 2010
- 5.6 Other Smoking Cessation Aids
  - 5.6.1 Smokeless Tobacco
    - 5.6.1.1 E-Cigarettes
    - 5.6.1.2 Snus/Snuff
    - 5.6.1.3 Gutkhas

5.6.2 CigRx Dietary Supplement

5.6.3 Dissolvable Tobacco

5.6.4 Behavioural Therapy

## **6. SMOKING CESSATION R&D PIPELINE ANALYSIS**

6.1 Nicotine Vaccines: Hype or Hope?

6.1.1 NicVAX (Nabi Biopharmaceuticals)

6.1.2 CYT002-NicQb (Cytos Biotechnology/Novartis)

6.1.3 TA-Nic (Celtic Pharma)

6.1.4 Niccine (Independent Pharmaceutica AB)

6.1.5 SEL-068 (Selecta Biosciences)

6.2 Monoamine Oxidase Inhibitors

6.2.1 EVT 302 (Evotec/Roche)

6.2.2 Selegiline (NIDA)

6.3 Cannabinoid Receptor-1 Antagonists

6.3.1 Rimonabant (Sanofi)

6.4 Dopamine D3 Antagonists

6.4.1 GSK598809 (GSK)

6.5 Opiate Antagonists

6.5.1 Naltrexone (Alkermes/Cephalon)

6.6 ARD-1600 (Aradigm)

6.7 EMB-001(Embera NeuroTherapeutics)

6.8 Meclizine (Duke University/Philip Morris Products)

6.9 Other Smoking Cessation Aids Under Development

6.9.1 X22TM (22nd Century Group)

6.9.2 Other Developments

## **7. SMOKING CESSATION INDUSTRY AND MARKET: QUALITATIVE ANALYSES**

7.1 Strengths of the Smoking Cessation Industry

7.1.1 Innovation in Smoking Cessation Therapies

7.1.2 Innovative Marketing

7.1.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy

7.1.4 OTC Switching

7.2 Weaknesses of the Smoking Cessation Industry

7.2.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking

7.2.2 Currently-Marketed Smoking Cessation Therapies - Relapse Rate

7.3 Opportunities for the Smoking Cessation Industry



- 7.3.1 Smoking is Prevalent Worldwide and Slowly Increasing
- 7.3.2 Countries with Untapped Smoking Cessation Market Potential
- 7.3.3 Growth of Emerging-Economy Smoking Cessation Markets
- 7.3.4 Health Effects of Tobacco
- 7.3.5 Economic Impact of Tobacco on Society
- 7.3.6 Framework Convention on Tobacco Control (FCTC)
- 7.3.7 Government-Sponsored Smoking Cessation Programmes
- 7.3.8 Increasing Tobacco Taxes
- 7.3.9 Smoking Bans
- 7.3.10 Warning Information on Tobacco Products
- 7.3.11 Bans on Tobacco Advertising, Promotion and Sponsorship
- 7.4 Threats to the Smoking Cessation Industry
  - 7.4.1 Concern over Side-Effects of Smoking Cessation Drugs
    - 7.4.1.1 Champix/Chantix
    - 7.4.1.2 Side-Effect Concerns for NRT and Bupropion
    - 7.4.1.3 The Result of Side-Effect Concerns
  - 7.4.2 Lack of Reimbursement for Smoking Cessation Therapies
  - 7.4.3 Traditional Smokeless Tobacco
    - 7.4.3.1 Snus and Gutkha
    - 7.4.3.2 Possible Impact of Greater Smokeless Tobacco Use
  - 7.4.4 The E-Cigarette
    - 7.4.4.1 The E-Cigarette Market
    - 7.4.4.2 Will E-Cigarettes Replace Smoking and Threaten the Smoking Cessation Drug Market?
    - 7.4.4.3 E-Cigarettes and Smoking Cessation Therapies

## **8. RESEARCH INTERVIEWS**

- 8.1 Interview with Dr Raafat Fahim, CEO, Nabi Biopharmaceuticals
  - 8.1.1 Nicotine Vaccines
  - 8.1.2 Smoking Cessation R&D Pipeline
  - 8.1.3 Major Areas of Focus
  - 8.1.4 Unmet Needs
  - 8.1.5 Opportunities for Revenue Growth
- 8.2 Interview with Mr Trevor Van Meirlo, CEO, EvolutionNHS
  - 8.2.1 Unmet Needs
  - 8.2.2 Major Areas of Focus
  - 8.2.3 Smoking Cessation R&D Pipeline
  - 8.2.4 Opportunities for Revenue Growth



#### 8.2.5 Market Drivers

8.3 Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London

##### 8.3.1 Unmet Needs

##### 8.3.2 Major Areas of Focus and R&D Pipeline

##### 8.3.3 Opportunities for Revenue Growth

##### 8.3.4 Market Drivers

## **9. CONCLUSIONS OF THE STUDY**

### 9.1 Smoking is the Main Cause of Preventable Deaths Worldwide

### 9.2 Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2012 to 2022

### 9.3 World Smoking Cessation Market: Prospects to 2022

### 9.4 Market Drivers

### 9.5 Leading and Emerging Smoking Cessation Markets

### 9.6 Concluding Remarks

## List Of Tables

### LIST OF TABLES

Table 3.1 World Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 3.2 Smoking Cessation Market Forecasts (\$bn): OTC and Rx Segments, 2010-2022
Table 3.3 Over-The-Counter Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 3.4 Prescription Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 3.5 Smoking Cessation Market Forecasts by Drug Type (\$bn), 2010-2022
Table 3.6 Nicotine Replacement Therapy Market Forecast (\$bn), 2010-2022
Table 3.7 Nicotine Receptor Partial Agonist Market Forecast (\$bn), 2010-2022
Table 3.8 Antidepressants for Smoking Cessation: Market Forecast (\$bn), 2010-2022
Table 4.1 Smoking Cessation Market Forecasts (\$bn) for Leading Countries, 2010-2022
Table 4.2 Smoking Cessation Market by Leading Countries: Sales (\$bn) & Market Shares (%), 2010
Table 4.3 US Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 4.4 Japanese Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 4.5 EU5 Smoking Cessation Market Forecasts (\$bn), 2010-2022
Table 4.6 UK Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 4.7 French Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 4.8 Spanish Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 4.9 Italian Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 4.10 German Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 4.11 Chinese Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 4.12 Indian Smoking Cessation Market Forecast (\$bn), 2010-2022
Table 5.1 Top 5 Smoking Cessation Drugs: Sales (\$bn) and Market Shares (%), 2010
Table 5.2 Nicotine Replacement Therapy Types, 2012
Table 5.3 NiQuitin/Nicabate/NicoDerm CQ NRT Brands, 2012
Table 5.4 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast (\$bn), 2010-2022
Table 5.5 Nicorette NRT Brands, 2012
Table 5.6 Nicorette Sales Forecast (\$bn), 2010-2022
Table 5.7 Nicotinell Sales Forecast (\$bn), 2010-2022
Table 5.8 Champix/Chantix Sales Forecast (\$bn), 2010-2022
Table 5.9 Zyban Sales Forecast (\$bn), 2010-2022
Table 5.10 Leading Smoking Cessation Brands: Sales Forecasts (\$bn), 2010-2022
Table 6.1 Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2012
Table 7.1 SWOT Analysis of the Industry and Market, 2012-2022
Table 7.2 STEP Analysis of the Industry and Market, 2012-2022

Table 9.1 Smoking Cessation Drug Market by Leading Countries: Sales (\$bn) and Market Shares (%), 2010, 2015 & 2022

## List Of Figures

### LIST OF FIGURES

Figure 2.1 Smoking-Related Health Disorders

Figure 3.1 World Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 3.2 Smoking Cessation Market Shares (%) by Use, 2010

Figure 3.3 Over-The-Counter Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 3.4 Prescription Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 3.5 Smoking Cessation Market Share (%) by Drug Type, 2010

Figure 3.6 Nicotine Replacement Therapy Market Forecast (\$bn), 2010-2022

Figure 3.7 Nicotine Receptor Partial Agonist Market Forecast (\$bn), 2010-2022

Figure 3.8 Antidepressants for Smoking Cessation: Market Forecast (\$bn), 2010-2022

Figure 4.1 Smoking Cessation Market Shares (%) by Leading Countries, 2010

Figure 4.2 Smoking Cessation Market Shares (%) by Leading Countries, 2015

Figure 4.3 Smoking Cessation Market Shares (%) by Leading Countries, 2022

Figure 4.4 US Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 4.5 Japanese Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 4.6 EU5 Smoking Cessation Market Forecasts (\$bn), 2010-2022

Figure 4.7 UK Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 4.8 French Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 4.9 Spanish Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 4.10 Italian Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 4.11 German Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 4.12 Chinese Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 4.13 Indian Smoking Cessation Market Forecast (\$bn), 2010-2022

Figure 5.1 Top 5 Smoking Cessation Drugs: Market Shares (%), 2010

Figure 5.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast (\$bn), 2010-2022

Figure 5.3 Nicorette Sales Forecast (\$bn), 2010-2022

Figure 5.4 Nicotinell Sales Forecast (\$bn), 2010-2022

Figure 5.5 Champix/Chantix Sales Forecast (\$bn), 2010-2022

Figure 5.6 Zyban Sales Forecast (\$bn), 2010-2022

Figure 9.1 Smoking Cessation Drugs: World Market Revenue Forecast (\$bn), 2010-2022

Figure 9.2 Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2010, 2015 & 2022

### COMPANIES LISTED

22nd Century Group  
Action on Smoking on Health (ASH)  
Alkermes  
American Heart Association (AHA)  
American Lung Association (ALA)  
Aradigm  
Australian Therapeutic Goods Administration  
Barts and The London School of Medicine and Dentistry  
Biovail  
Boots  
Ceejay Healthcare  
Celtic Pharma  
Centers for Disease Control and Prevention (CDC)  
Cephalon  
Chinese State Tobacco Monopoly Administration (STMA)  
Cytos Biotechnology  
Duke University  
Embera NeuroTherapeutics  
European Medicines Agency (EMA)  
Evolution NHS  
Evotec  
Food and Drug Administration (FDA)  
GlaxoSmithKline (GSK)  
Health Canada  
Independent Pharmaceutica AB  
Japanese Ministry of Health, Labour and Welfare (MHLW)  
Johnson & Johnson  
Karolinska Institutet  
LEO Pharma  
LSU Health Sciences Center - Shreveport  
Mayo Clinic  
Medicines and Healthcare Products Regulatory Agency (MHRA)  
Nabi Biopharmaceuticals  
National Cancer Institute (NCI)  
National Health Service (NHS)  
National Institute for Health and Clinical Excellence (NICE)  
National Institute on Drug Abuse (NIDA)  
National Tobacco Corp (China)  
Next Safety

Novartis  
Nulife  
Perrigo Company  
Pfizer  
Philip Morris Products S.A  
Queen Mary University of London  
R.J. Reynolds Tobacco Company  
Roche  
Rock Creek Pharmaceuticals  
Ruyan  
Sanofi  
Selecta Biosciences  
Sopharma  
Star Scientific  
Takeda  
The Cochrane Collaboration  
Tobacco Dependence Research Unit  
Wolfson Institute of Preventive Medicine  
World Health Organization (WHO)  
Zenara

## I would like to order

Product name: Smoking Cessation Drugs: World Market Prospects 2012-2022

Product link: <https://marketpublishers.com/r/S57F54886E8EN.html>

Price: US\$ 2,633.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S57F54886E8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970